Rezolute is trading at $4.49, up +13.38% in pre-market, with biotech-sector strength offering context; no confirmed company-specific overnight catalyst explains the move. - Supplied pre-market sector data showed XBI up 2.08%. - Rezolute was expected to report quarterly results on November 5, but the date was an estimate and no results were confirmed in available reporting. - Recent updates included Phase 3 upLIFT enrollment completion and upcoming investor conferences; neither was a new November 5 announcement.